Janssen Pharmaceutica, a division of the international Johnson & Johnson corporation, sold the rights to Nizoral dandruff shampoo in the EMEA region (Europe, Middle East, Africa) to the German company Stada, specializing in the production of generics. The deal was not disclosed: the owners of Stada - private investment companies Bain and Cinven - declared this data confidential. Nevertheless, according to sources of the agency Reuters, which first reported about the deal, it is about € 200 million.
According to the company, last year the sales of Nizoral shampoo in the EMEA region amounted to € 33 million.
In an interview with Reuters, Acting CEO of Stada Claudio Albrecht noted that the company can announce new purchase deals even before he leaves his post in two months, transferring the management to the permanent general manager appointed Peter Goldschmidt.
According to Mr. Albrecht, the company intends to regain a significant number of products previously released under a license. In addition, Stada is going to strengthen its position in some countries of Eastern Europe (Poland, Slovakia, Hungary) and in the UK on the eve of its withdrawal from the EU.
source: reuters.com
According to the company, last year the sales of Nizoral shampoo in the EMEA region amounted to € 33 million.
In an interview with Reuters, Acting CEO of Stada Claudio Albrecht noted that the company can announce new purchase deals even before he leaves his post in two months, transferring the management to the permanent general manager appointed Peter Goldschmidt.
According to Mr. Albrecht, the company intends to regain a significant number of products previously released under a license. In addition, Stada is going to strengthen its position in some countries of Eastern Europe (Poland, Slovakia, Hungary) and in the UK on the eve of its withdrawal from the EU.
source: reuters.com
